<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Urol</journal-id><journal-id journal-id-type="iso-abbrev">Eur. Urol</journal-id><journal-title-group><journal-title>European Urology</journal-title></journal-title-group><issn pub-type="ppub">0302-2838</issn><issn pub-type="epub">1873-7560</issn><publisher><publisher-name>Elsevier Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27720537</article-id><article-id pub-id-type="pmc">5289293</article-id><article-id pub-id-type="publisher-id">S0302-2838(16)30680-7</article-id><article-id pub-id-type="doi">10.1016/j.eururo.2016.09.040</article-id><article-categories><subj-group subj-group-type="heading"><subject>Platinum Priority – Prostate Cancer</subject><subj-group><subject><italic>Editorial by Matthew R. Cooperberg on pp. 389–390 of this issue</italic></subject></subj-group></subj-group></article-categories><title-group><article-title>Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Johnston</surname><given-names>Thomas J.</given-names></name><email>thomasjohnston1@nhs.net</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="fn0005" ref-type="fn">†</xref><xref rid="cor0005" ref-type="corresp">⁎</xref></contrib><contrib contrib-type="author"><name><surname>Shaw</surname><given-names>Greg L.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Lamb</surname><given-names>Alastair D.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0010" ref-type="aff">b</xref><xref rid="fn0005" ref-type="fn">†</xref></contrib><contrib contrib-type="author"><name><surname>Parashar</surname><given-names>Deepak</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author"><name><surname>Greenberg</surname><given-names>David</given-names></name><xref rid="aff0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author"><name><surname>Xiong</surname><given-names>Tengbin</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Edwards</surname><given-names>Alison L.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Gnanapragasam</surname><given-names>Vincent</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Holding</surname><given-names>Peter</given-names></name><xref rid="aff0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name><surname>Herbert</surname><given-names>Phillipa</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Michael</given-names></name><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Mizielinsk</surname><given-names>Elizabeth</given-names></name><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Lane</surname><given-names>J. Athene</given-names></name><xref rid="aff0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name><surname>Oxley</surname><given-names>Jon</given-names></name><xref rid="aff0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name><surname>Robinson</surname><given-names>Mary</given-names></name><xref rid="aff0040" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name><surname>Mason</surname><given-names>Malcolm</given-names></name><xref rid="aff0045" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name><surname>Staffurth</surname><given-names>John</given-names></name><xref rid="aff0045" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name><surname>Bollina</surname><given-names>Prasad</given-names></name><xref rid="aff0050" ref-type="aff">j</xref></contrib><contrib contrib-type="author"><name><surname>Catto</surname><given-names>James</given-names></name><xref rid="aff0055" ref-type="aff">k</xref></contrib><contrib contrib-type="author"><name><surname>Doble</surname><given-names>Andrew</given-names></name><xref rid="aff0060" ref-type="aff">l</xref></contrib><contrib contrib-type="author"><name><surname>Doherty</surname><given-names>Alan</given-names></name><xref rid="aff0065" ref-type="aff">m</xref></contrib><contrib contrib-type="author"><name><surname>Gillatt</surname><given-names>David</given-names></name><xref rid="aff0070" ref-type="aff">n</xref></contrib><contrib contrib-type="author"><name><surname>Kockelbergh</surname><given-names>Roger</given-names></name><xref rid="aff0075" ref-type="aff">o</xref></contrib><contrib contrib-type="author"><name><surname>Kynaston</surname><given-names>Howard</given-names></name><xref rid="aff0080" ref-type="aff">p</xref></contrib><contrib contrib-type="author"><name><surname>Prescott</surname><given-names>Steve</given-names></name><xref rid="aff0085" ref-type="aff">q</xref></contrib><contrib contrib-type="author"><name><surname>Paul</surname><given-names>Alan</given-names></name><xref rid="aff0085" ref-type="aff">q</xref></contrib><contrib contrib-type="author"><name><surname>Powell</surname><given-names>Philip</given-names></name><xref rid="aff0090" ref-type="aff">r</xref></contrib><contrib contrib-type="author"><name><surname>Rosario</surname><given-names>Derek</given-names></name><xref rid="aff0055" ref-type="aff">k</xref></contrib><contrib contrib-type="author"><name><surname>Rowe</surname><given-names>Edward</given-names></name><xref rid="aff0070" ref-type="aff">n</xref></contrib><contrib contrib-type="author"><name><surname>Donovan</surname><given-names>Jenny L.</given-names></name><xref rid="aff0030" ref-type="aff">f</xref><xref rid="fn0005" ref-type="fn">†</xref></contrib><contrib contrib-type="author"><name><surname>Hamdy</surname><given-names>Freddie C.</given-names></name><xref rid="aff0025" ref-type="aff">e</xref><xref rid="fn0005" ref-type="fn">†</xref></contrib><contrib contrib-type="author"><name><surname>Neal</surname><given-names>David E.</given-names></name><email>den22@cam.ac.uk</email><xref rid="aff0005" ref-type="aff">a</xref><xref rid="aff0025" ref-type="aff">e</xref><xref rid="fn0005" ref-type="fn">†</xref><xref rid="cor0005" ref-type="corresp">⁎</xref></contrib><contrib contrib-type="author"><collab>for the ProtecT study group</collab><xref rid="fn0010" ref-type="fn">§</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Academic Urology Group, University of Cambridge, Cambridge, UK</aff><aff id="aff0010"><label>b</label>Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK</aff><aff id="aff0015"><label>c</label>Statistics and Epidemiology Unit &amp; Cancer Research Centre, University of Warwick, Coventry, UK</aff><aff id="aff0020"><label>d</label>National Cancer Registration Service – Eastern Office, Public Health England, Cambridge, UK</aff><aff id="aff0025"><label>e</label>Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK</aff><aff id="aff0030"><label>f</label>School of Social and Community Medicine, University of Bristol, Bristol, UK</aff><aff id="aff0035"><label>g</label>Department of Cellular Pathology, North Bristol NHS Trust, Bristol, UK</aff><aff id="aff0040"><label>h</label>Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK</aff><aff id="aff0045"><label>i</label>Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK</aff><aff id="aff0050"><label>j</label>Department of Urology and Surgery, Western General Hospital, University of Edinburgh, Edinburgh, UK</aff><aff id="aff0055"><label>k</label>Academic Urology Unit, University of Sheffield, Sheffield, UK</aff><aff id="aff0060"><label>l</label>Department of Urology, Addenbrooke's Hospital, Cambridge, UK</aff><aff id="aff0065"><label>m</label>Department of Urology, Queen Elizabeth Hospital, Birmingham, UK</aff><aff id="aff0070"><label>n</label>Department of Urology, Southmead Hospital and Bristol Urological Institute, Bristol, UK</aff><aff id="aff0075"><label>o</label>Department of Urology, University Hospitals of Leicester, Leicester, UK</aff><aff id="aff0080"><label>p</label>Department of Urology, Cardiff and Vale University Health Board, Cardiff, UK</aff><aff id="aff0085"><label>q</label>Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK</aff><aff id="aff0090"><label>r</label>Department of Urology, Freeman Hospital, Newcastle-upon-Tyne, UK</aff><author-notes><corresp id="cor0005"><label>⁎</label>Corresponding authors. Academic Urology Group, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. <email>thomasjohnston1@nhs.net</email><email>den22@cam.ac.uk</email></corresp><fn id="fn0005"><label>†</label><p id="npar0020">These authors contributed equally to this work.</p></fn><fn id="fn0010"><label>§</label><p id="npar0025">The members of the ProtecT study group are listed in the Supplementary material.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>3</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2017</year></pub-date><volume>71</volume><issue>3</issue><fpage>381</fpage><lpage>388</lpage><history><date date-type="accepted"><day>26</day><month>9</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 Elsevier B.V. on behalf of European Association of Urology. All rights reserved.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>European Association of Urology</copyright-holder><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title><offsets xml_i="10305" xml_f="10315" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="10326" xml_f="10453" txt_i="22" txt_f="149">Early detection and treatment of asymptomatic men with advanced and high-risk prostate cancer (PCa) may improve survival rates.</offsets></p></sec><sec><title><offsets xml_i="10475" xml_f="10484" txt_i="151" txt_f="160">Objective</offsets></title><p><offsets xml_i="10495" xml_f="10655" txt_i="161" txt_f="321">To determine outcomes for men diagnosed with advanced PCa following prostate-specific antigen (PSA) testing who were excluded from the ProtecT randomised trial.</offsets></p></sec><sec><title><offsets xml_i="10677" xml_f="10710" txt_i="323" txt_f="356">Design, setting, and participants</offsets></title><p><offsets xml_i="10721" xml_f="10905" txt_i="357" txt_f="541">Mortality was compared for 492 men followed up for a median of 7.4 yr to a contemporaneous cohort of men from the UK Anglia Cancer Network (ACN) and with a matched subset from the ACN.</offsets></p></sec><sec><title><offsets xml_i="10927" xml_f="10972" txt_i="543" txt_f="588">Outcome measurements and statistical analysis</offsets></title><p><offsets xml_i="10983" xml_f="11104" txt_i="589" txt_f="710">PCa-specific and all-cause mortality were compared using Kaplan-Meier analysis and Cox's proportional hazards regression.</offsets></p></sec><sec><title><offsets xml_i="11126" xml_f="11149" txt_i="712" txt_f="735">Results and limitations</offsets></title><p><offsets xml_i="11160" xml_f="11373" txt_i="736" txt_f="949">Of the 492 men excluded from the ProtecT cohort, 37 (8%) had metastases (N1, M0 = 5, M1 = 32) and 305 had locally advanced disease (62%). The median PSA was 17 μg/l. Treatments included radical prostatectomy (RP; </offsets><italic><offsets xml_i="11381" xml_f="11382" txt_i="949" txt_f="950">n</offsets></italic><offsets xml_i="11391" xml_f="11422" txt_i="950" txt_f="981"> = 54; 11%), radiotherapy (RT; </offsets><italic><offsets xml_i="11430" xml_f="11431" txt_i="981" txt_f="982">n</offsets></italic><offsets xml_i="11440" xml_f="11489" txt_i="982" txt_f="1031"> = 245; 50%), androgen deprivation therapy (ADT; </offsets><italic><offsets xml_i="11497" xml_f="11498" txt_i="1031" txt_f="1032">n</offsets></italic><offsets xml_i="11507" xml_f="11539" txt_i="1032" txt_f="1064"> = 122; 25%), other treatments (</offsets><italic><offsets xml_i="11547" xml_f="11548" txt_i="1064" txt_f="1065">n</offsets></italic><offsets xml_i="11557" xml_f="11582" txt_i="1065" txt_f="1090"> = 11; 2%), and unknown (</offsets><italic><offsets xml_i="11590" xml_f="11591" txt_i="1090" txt_f="1091">n</offsets></italic><offsets xml_i="11600" xml_f="12004" txt_i="1091" txt_f="1495"> = 60; 12%). There were 49 PCa-specific deaths (10%), of whom 14 men had received radical treatment (5%); and 129 all-cause deaths (26%). In matched ProtecT and ACN cohorts, 37 (9%) and 64 (16%), respectively, died of PCa, while 89 (22%) and 103 (26%) died of all causes. ProtecT men had a 45% lower risk of death from PCa compared to matched cases (hazard ratio 0.55, 95% confidence interval 0.38–0.83; </offsets><italic><offsets xml_i="12012" xml_f="12013" txt_i="1495" txt_f="1496">p</offsets></italic><offsets xml_i="12022" xml_f="12129" txt_i="1496" txt_f="1603"> = 0.0037), but mortality was similar in those treated radically. The nonrandomised design is a limitation.</offsets></p></sec><sec><title><offsets xml_i="12151" xml_f="12162" txt_i="1605" txt_f="1616">Conclusions</offsets></title><p><offsets xml_i="12173" xml_f="12508" txt_i="1617" txt_f="1952">Men with PSA-detected advanced PCa excluded from ProtecT and treated radically had low rates of PCa death at 7.4-yr follow-up. Among men who underwent nonradical treatment, the ProtecT group had a lower rate of PCa death. Early detection through PSA testing, leadtime bias, and group heterogeneity are possible factors in this finding.</offsets></p></sec><sec><title><offsets xml_i="12530" xml_f="12545" txt_i="1954" txt_f="1969">Patient summary</offsets></title><p><offsets xml_i="12556" xml_f="12755" txt_i="1970" txt_f="2169">Prostate cancer that has spread outside the prostate gland without causing symptoms can be detected via prostate-specific antigen testing and treated, leading to low rates of death from this disease.</offsets></p></sec></abstract><abstract abstract-type="teaser" id="abs0005"><title><offsets xml_i="12829" xml_f="12846" txt_i="2182" txt_f="2199">Take Home Message</offsets></title><p><offsets xml_i="12857" xml_f="13057" txt_i="2200" txt_f="2400">Early detection and treatment of asymptomatic men with advanced and high-risk prostate cancer lead to good survival rates and are indicative of improved survival compared to men presenting clinically.</offsets></p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>Prostate cancer</kwd><kwd>Prostate-specific antigen screening</kwd><kwd>Survival</kwd></kwd-group></article-meta><notes><p id="misc0005"><bold>Associate Editor:</bold> Stephen Boorjian</p></notes></front><body><sec id="sec0005"><label><offsets xml_i="13359" xml_f="13360" txt_i="2408" txt_f="2409">1</offsets></label><title><offsets xml_i="13375" xml_f="13387" txt_i="2409" txt_f="2421">Introduction</offsets></title><p><offsets xml_i="13398" xml_f="13479" txt_i="2422" txt_f="2503">Population-based prostate specific antigen (PSA) screening remains controversial </offsets><xref rid="bib0130" ref-type="bibr"><offsets xml_i="13515" xml_f="13518" txt_i="2503" txt_f="2506">[1]</offsets></xref><offsets xml_i="13525" xml_f="13790" txt_i="2506" txt_f="2771">. Although screening in the European Randomised Study of Screening for Prostate Cancer (ERSPC) detected high numbers of prostate cancers (PCas) and lower mortality from that disease, the majority of cancers were indolent, leading to overdetection and overtreatment </offsets><xref rid="bib0135" ref-type="bibr"><offsets xml_i="13826" xml_f="13829" txt_i="2771" txt_f="2774">[2]</offsets></xref><offsets xml_i="13836" xml_f="13838" txt_i="2774" txt_f="2776">, </offsets><xref rid="bib0140" ref-type="bibr"><offsets xml_i="13874" xml_f="13877" txt_i="2776" txt_f="2779">[3]</offsets></xref><offsets xml_i="13884" xml_f="14100" txt_i="2779" txt_f="2995">. The Prostate, Lung and Ovarian cancer screening study (PCLO) reported no survival benefit after 11.5 yr of follow-up, but there was widespread contamination in the control arm with previous PSA testing (up to 90%) </offsets><xref rid="bib0135" ref-type="bibr"><offsets xml_i="14136" xml_f="14139" txt_i="2995" txt_f="2998">[2]</offsets></xref><offsets xml_i="14146" xml_f="14148" txt_i="2998" txt_f="3000">, </offsets><xref rid="bib0140" ref-type="bibr"><offsets xml_i="14184" xml_f="14187" txt_i="3000" txt_f="3003">[3]</offsets></xref><offsets xml_i="14194" xml_f="14195" txt_i="3003" txt_f="3004">.</offsets></p><p><offsets xml_i="14202" xml_f="14621" txt_i="3005" txt_f="3424">There is uncertainty regarding the effectiveness of treatments for PSA-detected clinically localised PCa. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) reported no survival benefit after 12 yr of follow-up among men with mainly low-risk disease treated with surgery or observation, although there was high all-cause mortality in both arms, suggesting that men with major comorbidities were included </offsets><xref rid="bib0145" ref-type="bibr"><offsets xml_i="14657" xml_f="14660" txt_i="3424" txt_f="3427">[4]</offsets></xref><offsets xml_i="14667" xml_f="14755" txt_i="3427" txt_f="3515">. No randomised trials have compared different radical treatments for men with advanced </offsets><xref rid="bib0150" ref-type="bibr"><offsets xml_i="14791" xml_f="14794" txt_i="3515" txt_f="3518">[5]</offsets></xref><offsets xml_i="14801" xml_f="14803" txt_i="3518" txt_f="3520">, </offsets><xref rid="bib0155" ref-type="bibr"><offsets xml_i="14839" xml_f="14842" txt_i="3520" txt_f="3523">[6]</offsets></xref><offsets xml_i="14849" xml_f="14932" txt_i="3523" txt_f="3606"> or high-risk disease, and retrospective studies have reported conflicting results </offsets><xref rid="bib0160" ref-type="bibr"><offsets xml_i="14968" xml_f="14971" txt_i="3606" txt_f="3609">[7]</offsets></xref><offsets xml_i="14978" xml_f="14980" txt_i="3609" txt_f="3611">, </offsets><xref rid="bib0165" ref-type="bibr"><offsets xml_i="15016" xml_f="15019" txt_i="3611" txt_f="3614">[8]</offsets></xref><offsets xml_i="15026" xml_f="15028" txt_i="3614" txt_f="3616">, </offsets><xref rid="bib0170" ref-type="bibr"><offsets xml_i="15064" xml_f="15067" txt_i="3616" txt_f="3619">[9]</offsets></xref><offsets xml_i="15074" xml_f="15076" txt_i="3619" txt_f="3621">, </offsets><xref rid="bib0175" ref-type="bibr"><offsets xml_i="15112" xml_f="15116" txt_i="3621" txt_f="3625">[10]</offsets></xref><offsets xml_i="15123" xml_f="15350" txt_i="3625" txt_f="3852">. There is uncertainty regarding outcomes among men with higher-risk PCa detected via PSA screening, although a subgroup analysis of PIVOT suggested benefit in favour of radical treatment for intermediate- or high-risk disease </offsets><xref rid="bib0145" ref-type="bibr"><offsets xml_i="15386" xml_f="15389" txt_i="3852" txt_f="3855">[4]</offsets></xref><offsets xml_i="15396" xml_f="15397" txt_i="3855" txt_f="3856">.</offsets></p><p><offsets xml_i="15404" xml_f="15456" txt_i="3857" txt_f="3909">Details of the ProtecT trial are reported elsewhere </offsets><xref rid="bib0180" ref-type="bibr"><offsets xml_i="15492" xml_f="15496" txt_i="3909" txt_f="3913">[11]</offsets></xref><offsets xml_i="15503" xml_f="15505" txt_i="3913" txt_f="3915">, </offsets><xref rid="bib0185" ref-type="bibr"><offsets xml_i="15541" xml_f="15545" txt_i="3915" txt_f="3919">[12]</offsets></xref><offsets xml_i="15552" xml_f="15554" txt_i="3919" txt_f="3921">, </offsets><xref rid="bib0190" ref-type="bibr"><offsets xml_i="15590" xml_f="15594" txt_i="3921" txt_f="3925">[13]</offsets></xref><offsets xml_i="15601" xml_f="15603" txt_i="3925" txt_f="3927">, </offsets><xref rid="bib0195" ref-type="bibr"><offsets xml_i="15639" xml_f="15643" txt_i="3927" txt_f="3931">[14]</offsets></xref><offsets xml_i="15650" xml_f="15652" txt_i="3931" txt_f="3933">, </offsets><xref rid="bib0200" ref-type="bibr"><offsets xml_i="15688" xml_f="15692" txt_i="3933" txt_f="3937">[15]</offsets></xref><offsets xml_i="15699" xml_f="16177" txt_i="3937" txt_f="4415">. Men with metastatic or locally advanced disease (cT3–4) and/or PSA ≥20 μg/l were excluded from ProtecT, along with men considered by local urologists to be unsuitable for the trial because of their clinical features. These men excluded from the ProtecT randomised trial but diagnosed contemporaneously provide a unique opportunity to assess the outcomes of advanced and high-risk disease at diagnosis in a population with very low rates of opportunistic PSA screening (8–13%) </offsets><xref rid="bib0185" ref-type="bibr"><offsets xml_i="16213" xml_f="16217" txt_i="4415" txt_f="4419">[12]</offsets></xref><offsets xml_i="16224" xml_f="16226" txt_i="4419" txt_f="4421">, </offsets><xref rid="bib0205" ref-type="bibr"><offsets xml_i="16262" xml_f="16266" txt_i="4421" txt_f="4425">[16]</offsets></xref><offsets xml_i="16273" xml_f="16274" txt_i="4425" txt_f="4426">.</offsets></p><p><offsets xml_i="16281" xml_f="16523" txt_i="4427" txt_f="4669">Here we present survival data for these men in comparison to data for a contemporaneous cohort from the UK Anglia Cancer Network (ACN), which has generally low rates of PSA testing, and with a matched ACN cohort with similar disease features.</offsets></p></sec><sec id="sec0010"><label><offsets xml_i="16558" xml_f="16559" txt_i="4671" txt_f="4672">2</offsets></label><title><offsets xml_i="16574" xml_f="16594" txt_i="4672" txt_f="4692">Patients and methods</offsets></title><sec id="sec0015"><label><offsets xml_i="16627" xml_f="16630" txt_i="4693" txt_f="4696">2.1</offsets></label><title><offsets xml_i="16645" xml_f="16660" txt_i="4696" txt_f="4711">Case population</offsets></title><p><offsets xml_i="16671" xml_f="16902" txt_i="4712" txt_f="4943">The ProtecT trial compares active monitoring, conformal external-beam radical radiotherapy (RT) with or without androgen deprivation therapy (ADT) and radical prostatectomy (RP) treatments for PSA-detected clinically localised PCa </offsets><xref rid="bib0185" ref-type="bibr"><offsets xml_i="16938" xml_f="16942" txt_i="4943" txt_f="4947">[12]</offsets></xref><offsets xml_i="16949" xml_f="17567" txt_i="4947" txt_f="5565">. Between 2001 and 2009 there were 82 429 asymptomatic men aged 50 and 69 yr who underwent PSA testing, and those with PSA ≥3 μg/l proceeded to biopsy. Participants with initial PSA ≥20 μg/l or found to have locally advanced (T3–4) PCa or distant disease (N1 or M1) were ineligible and referred for standard care. The majority had locally advanced PCa; a small proportion (5%) were classed as at high risk of having non–organ-confined disease and were felt to be unsuitable for randomisation. In total, 513 men (PSA ≥20 μg/l, or locally advanced cT3–4 PCa, or Gleason ≥8, or N1/M1 disease) were excluded from ProtecT (</offsets><xref rid="tbl0005" ref-type="table"><offsets xml_i="17604" xml_f="17611" txt_i="5565" txt_f="5572">Table 1</offsets></xref><offsets xml_i="17618" xml_f="17684" txt_i="5572" txt_f="5638">). These men form the ProtecT advanced cases cohort reported here.</offsets></p><p><offsets xml_i="17691" xml_f="17936" txt_i="5639" txt_f="5884">Information on treatment and survival was obtained during annual ProtecT follow-up and checked using the English National Cancer Online Registration Environment database in the Eastern Office of the National Cancer Registration Service (NCRS-E) </offsets><xref rid="bib0200" ref-type="bibr"><offsets xml_i="17972" xml_f="17976" txt_i="5884" txt_f="5888">[15]</offsets></xref><offsets xml_i="17983" xml_f="18109" txt_i="5888" txt_f="6014">. Cause of death was determined by review of certification by two independent clinicians blinded to study group and treatment.</offsets></p></sec><sec id="sec0020"><label><offsets xml_i="18144" xml_f="18147" txt_i="6016" txt_f="6019">2.2</offsets></label><title><offsets xml_i="18162" xml_f="18183" txt_i="6019" txt_f="6040">Comparison population</offsets></title><p><offsets xml_i="18194" xml_f="18307" txt_i="6041" txt_f="6154">Comparison patients (controls) were identified by the NCRS-E by interrogation of the Anglia Cancer Network (ACN) </offsets><xref rid="bib0175" ref-type="bibr"><offsets xml_i="18343" xml_f="18347" txt_i="6154" txt_f="6158">[10]</offsets></xref><offsets xml_i="18354" xml_f="18699" txt_i="6158" txt_f="6503"> for a contemporary cohort of men with comparable age and year of diagnosis and similarly advanced and high-risk disease features: PSA ≥20 ng/ml, locally advanced disease (cT3–4), Gleason score ≥8, or N1/M1 disease. The ACN cases were judged to be a suitable comparative cohort because of low rates of PSA testing (10–13%) in the ACN population </offsets><xref rid="bib0185" ref-type="bibr"><offsets xml_i="18735" xml_f="18739" txt_i="6503" txt_f="6507">[12]</offsets></xref><offsets xml_i="18746" xml_f="18748" txt_i="6507" txt_f="6509">, </offsets><xref rid="bib0210" ref-type="bibr"><offsets xml_i="18784" xml_f="18788" txt_i="6509" txt_f="6513">[17]</offsets></xref><offsets xml_i="18795" xml_f="18821" txt_i="6513" txt_f="6539"> (Supplementary material).</offsets></p><p><offsets xml_i="18828" xml_f="18933" txt_i="6540" txt_f="6645">The ProtecT trial was approved by the East Midlands Ethics Committee (Derby, UK; record number 01/4/025).</offsets></p></sec><sec id="sec0025"><label><offsets xml_i="18968" xml_f="18971" txt_i="6647" txt_f="6650">2.3</offsets></label><title><offsets xml_i="18986" xml_f="19006" txt_i="6650" txt_f="6670">Statistical analysis</offsets></title><p><offsets xml_i="19017" xml_f="19030" txt_i="6671" txt_f="6684">We used the χ</offsets><sup><offsets xml_i="19035" xml_f="19036" txt_i="6684" txt_f="6685">2</offsets></sup><offsets xml_i="19042" xml_f="20100" txt_i="6685" txt_f="7743"> test for heterogeneity to assess baseline differences between cases and controls. The primary analysis compared risk of death from PCa and all causes between ProtecT cases and ACN controls with clinically detected PCa. Cases and controls were matched 1:1 according to age, year of diagnosis, PSA, Gleason score, and clinical stage. Survival estimates were carried out using Kaplan-Meier methods, with group differences (unmatched and matched) expressed as the hazard ratio (HR) with 95% confidence interval (CI) and compared using the log-rank test. Cox proportional hazards regression models (univariable and multivariable) were also fitted to estimate survival for the unmatched ProtecT cases and ACN controls adjusted for the above variables, with results expressed as HR with 95% CI. A sensitivity Cox regression survival analysis was performed for a subset of the unmatched groups separated for N0M0 and N1 or M1 disease, and was also fitted for the matched groups with further adjustment for treatment allocation. Fisher's exact test and a two-sample </offsets><italic><offsets xml_i="20108" xml_f="20109" txt_i="7743" txt_f="7744">z</offsets></italic><offsets xml_i="20118" xml_f="20478" txt_i="7744" txt_f="8104">-test of proportions were used to assess differences between treatments received in the matched groups. A secondary analysis assessed biochemical-free and castrate-resistant–free survival within treatment groups. Data for patients who died from PCa or other causes were censored at date of death. All tests were two-sided, with statistical significance set at </offsets><italic><offsets xml_i="20486" xml_f="20487" txt_i="8104" txt_f="8105">p</offsets></italic><offsets xml_i="20496" xml_f="20626" txt_i="8105" txt_f="8232"> &lt; 0.05. All analyses were performed using IBM SPSS for Windows, version 22.0, GraphPad Prism, version 6, and STATA version 14.</offsets></p></sec></sec><sec id="sec0030"><label><offsets xml_i="20667" xml_f="20668" txt_i="8235" txt_f="8236">3</offsets></label><title><offsets xml_i="20683" xml_f="20690" txt_i="8236" txt_f="8243">Results</offsets></title><sec id="sec0035"><label><offsets xml_i="20723" xml_f="20726" txt_i="8244" txt_f="8247">3.1</offsets></label><title><offsets xml_i="20741" xml_f="20785" txt_i="8247" txt_f="8291">ProtecT case and ACN control characteristics</offsets></title><p><offsets xml_i="20796" xml_f="20856" txt_i="8292" txt_f="8352">The flow of the patients through the study is summarised in </offsets><xref rid="fig0005" ref-type="fig"><offsets xml_i="20891" xml_f="20899" txt_i="8352" txt_f="8360">Figure 1</offsets></xref><offsets xml_i="20906" xml_f="21304" txt_i="8360" txt_f="8758">. There were 513 ProtecT advanced cases, of whom 21 were excluded because of incomplete data at presentation. For the remaining 492 cases, the mean age was 64 yr (interquartile range [IQR] 61–68); median PSA was 17 ng/ml (mean 33, IQR 8–32 ng/ml); 43% had PSA ≥20 ng/ml; 62% had clinical stage ≥T3; 23% had a Gleason score ≥8; and 8% had N1 or M1 disease. Median follow-up was 7.4 yr (IQR 5.5–9.7; </offsets><xref rid="tbl0005" ref-type="table"><offsets xml_i="21341" xml_f="21348" txt_i="8758" txt_f="8765">Table 1</offsets></xref><offsets xml_i="21355" xml_f="21587" txt_i="8765" txt_f="8997">). For analysis of biochemical recurrence, data on primary treatment were available for 432 out of 492 ProtecT cases (88%), and data on PSA follow-up and on neoadjuvant, adjuvant, or salvage therapies for 352 out of 492 cases (72%).</offsets></p><p><offsets xml_i="21594" xml_f="21861" txt_i="8998" txt_f="9265">We identified 3978 ACN controls aged 50–72 yr with clinically detected PCa. Median follow-up was 5 yr (IQR 3.1–7.8). There were differences in baseline characteristics: ACN controls were older, had higher PSA levels, higher Gleason scores, and higher PCa stages (all </offsets><italic><offsets xml_i="21869" xml_f="21870" txt_i="9265" txt_f="9266">p</offsets></italic><offsets xml_i="21879" xml_f="21933" txt_i="9266" txt_f="9317"> &lt; 0.0002). Accordingly, we matched ProtecT cases (</offsets><italic><offsets xml_i="21941" xml_f="21942" txt_i="9317" txt_f="9318">n</offsets></italic><offsets xml_i="21951" xml_f="21976" txt_i="9318" txt_f="9343"> = 401) to ACN controls (</offsets><italic><offsets xml_i="21984" xml_f="21985" txt_i="9343" txt_f="9344">n</offsets></italic><offsets xml_i="21994" xml_f="22026" txt_i="9344" txt_f="9376"> = 401) across these variables (</offsets><xref rid="tbl0005" ref-type="table"><offsets xml_i="22063" xml_f="22070" txt_i="9376" txt_f="9383">Table 1</offsets></xref><offsets xml_i="22077" xml_f="22275" txt_i="9383" txt_f="9581">). The median follow-up for the matched cohorts was 7.6 yr (IQR 5.1–9.8). There were complete data on primary treatment for 352 of 401 (88%) matched ProtecT cases and 391 of 401 (98%) ACN controls (</offsets><xref rid="tbl0010" ref-type="table"><offsets xml_i="22312" xml_f="22319" txt_i="9581" txt_f="9588">Table 2</offsets></xref><offsets xml_i="22326" xml_f="22328" txt_i="9588" txt_f="9590">).</offsets></p></sec><sec id="sec0040"><label><offsets xml_i="22363" xml_f="22366" txt_i="9592" txt_f="9595">3.2</offsets></label><title><offsets xml_i="22381" xml_f="22398" txt_i="9595" txt_f="9612">Survival analysis</offsets></title><sec id="sec0045"><label><offsets xml_i="22431" xml_f="22436" txt_i="9613" txt_f="9618">3.2.1</offsets></label><title><offsets xml_i="22451" xml_f="22473" txt_i="9618" txt_f="9640">ProtecT advanced cases</offsets></title><p><offsets xml_i="22484" xml_f="22885" txt_i="9641" txt_f="10042">Of the 492 ProtecT men, 54 (11%) had radical prostatectomy (RP); 245 (50%) had RT, of whom 93% had neoadjuvant and adjuvant ADT; 122 (25%) had ADT alone; five (1%) had primary chemotherapy; six (1%) had other treatment (high-intensity focused ultrasound or monitoring); and for 60 (12%) the treatment was unknown. We were unable to demonstrate a difference in PCa-specific (HR 0.95, 95% CI 0.22–4.12; </offsets><italic><offsets xml_i="22893" xml_f="22894" txt_i="10042" txt_f="10043">p</offsets></italic><offsets xml_i="22903" xml_f="22963" txt_i="10043" txt_f="10103"> = 0.94) or all-cause mortality (HR 0.69, 95% CI 0.29–1.67; </offsets><italic><offsets xml_i="22971" xml_f="22972" txt_i="10103" txt_f="10104">p</offsets></italic><offsets xml_i="22981" xml_f="23020" txt_i="10104" txt_f="10143"> = 0.41) between the RP and RT groups (</offsets><xref rid="fig0010" ref-type="fig"><offsets xml_i="23055" xml_f="23061" txt_i="10143" txt_f="10149">Fig. 2</offsets></xref><offsets xml_i="23068" xml_f="23109" txt_i="10149" txt_f="10190">A,2B). Men who received RP were younger (</offsets><italic><offsets xml_i="23117" xml_f="23118" txt_i="10190" txt_f="10191">p</offsets></italic><offsets xml_i="23127" xml_f="23158" txt_i="10191" txt_f="10219"> &lt; 0.01) and had lower PSA (</offsets><italic><offsets xml_i="23166" xml_f="23167" txt_i="10219" txt_f="10220">p</offsets></italic><offsets xml_i="23176" xml_f="23277" txt_i="10220" txt_f="10318"> &lt; 0.0001) compared to the RT group, but no significant difference was observed in Gleason score (</offsets><italic><offsets xml_i="23285" xml_f="23286" txt_i="10318" txt_f="10319">p</offsets></italic><offsets xml_i="23295" xml_f="23314" txt_i="10319" txt_f="10338"> = 0.84) or stage (</offsets><italic><offsets xml_i="23322" xml_f="23323" txt_i="10338" txt_f="10339">p</offsets></italic><offsets xml_i="23332" xml_f="23364" txt_i="10339" txt_f="10371"> = 0.19; Supplementary Table 1).</offsets></p><p><offsets xml_i="23371" xml_f="23664" txt_i="10372" txt_f="10665">All-cause mortality was 7% (4/54) among men who underwent RP (2 died of PCa; 4%) and 15% (37/245) among those who received RT (12 died of PCa; 5%). All-cause mortality was higher among men who underwent nonradical treatment (51/133; 38%) and men whose treatments were unknown (25/60; 42%; all </offsets><italic><offsets xml_i="23672" xml_f="23673" txt_i="10665" txt_f="10666">p</offsets></italic><offsets xml_i="23682" xml_f="23696" txt_i="10666" txt_f="10677"> &lt; 0.0001; </offsets><xref rid="fig0010" ref-type="fig"><offsets xml_i="23731" xml_f="23737" txt_i="10677" txt_f="10683">Fig. 2</offsets></xref><offsets xml_i="23744" xml_f="23785" txt_i="10683" txt_f="10724">A,2B). Men treated using ADT were older (</offsets><italic><offsets xml_i="23793" xml_f="23794" txt_i="10724" txt_f="10725">p</offsets></italic><offsets xml_i="23803" xml_f="23832" txt_i="10725" txt_f="10754"> = 0.01) and had higher PSA (</offsets><italic><offsets xml_i="23840" xml_f="23841" txt_i="10754" txt_f="10755">p</offsets></italic><offsets xml_i="23850" xml_f="23880" txt_i="10755" txt_f="10782"> &lt; 0.0001), Gleason score (</offsets><italic><offsets xml_i="23888" xml_f="23889" txt_i="10782" txt_f="10783">p</offsets></italic><offsets xml_i="23898" xml_f="23919" txt_i="10783" txt_f="10804"> = 0.05), and stage (</offsets><italic><offsets xml_i="23927" xml_f="23928" txt_i="10804" txt_f="10805">p</offsets></italic><offsets xml_i="23937" xml_f="24022" txt_i="10805" txt_f="10887"> &lt; 0.0001) compared to men who received radical treatment (Supplementary Table 1).</offsets></p></sec><sec id="sec0050"><label><offsets xml_i="24057" xml_f="24062" txt_i="10889" txt_f="10894">3.2.2</offsets></label><title><offsets xml_i="24077" xml_f="24137" txt_i="10894" txt_f="10954">Comparison with ACN controls: Kaplan-Meier survival analysis</offsets></title><p><offsets xml_i="24148" xml_f="24215" txt_i="10955" txt_f="11022">We found lower risks of death from PCa (HR 0.29, 95% CI 0.38–0.53; </offsets><italic><offsets xml_i="24223" xml_f="24224" txt_i="11022" txt_f="11023">p</offsets></italic><offsets xml_i="24233" xml_f="24295" txt_i="11023" txt_f="11082"> &lt; 0.0001) and from all causes (HR 0.45, 95% CI 0.48–0.63; </offsets><italic><offsets xml_i="24303" xml_f="24304" txt_i="11082" txt_f="11083">p</offsets></italic><offsets xml_i="24313" xml_f="24426" txt_i="11083" txt_f="11193"> &lt; 0.0001) among ProtecT cases compared to unmatched ACN controls (Supplementary Fig. 1A,1B). After matching (</offsets><xref rid="tbl0005" ref-type="table"><offsets xml_i="24463" xml_f="24470" txt_i="11193" txt_f="11200">Table 1</offsets></xref><offsets xml_i="24477" xml_f="24554" txt_i="11200" txt_f="11277">) we observed a 45% lower rate of death from PCa (HR 0.55, 95% CI 0.38–0.83; </offsets><italic><offsets xml_i="24562" xml_f="24563" txt_i="11277" txt_f="11278">p</offsets></italic><offsets xml_i="24572" xml_f="24675" txt_i="11278" txt_f="11381"> = 0.0037), but were unable to demonstrate a difference in all-cause deaths (HR 0.83; 95% CI 0.63–1.1; </offsets><italic><offsets xml_i="24683" xml_f="24684" txt_i="11381" txt_f="11382">p</offsets></italic><offsets xml_i="24693" xml_f="24760" txt_i="11382" txt_f="11449"> = 0.19) between matched ProtecT cases and ACN controls at 7.6 yr (</offsets><xref rid="fig0015" ref-type="fig"><offsets xml_i="24795" xml_f="24801" txt_i="11449" txt_f="11455">Fig. 3</offsets></xref><offsets xml_i="24808" xml_f="24814" txt_i="11455" txt_f="11461">A,3B).</offsets></p><p><offsets xml_i="24821" xml_f="24929" txt_i="11462" txt_f="11570">There was a similar proportion of men who received radical and nonradical treatments in the matched groups (</offsets><italic><offsets xml_i="24937" xml_f="24938" txt_i="11570" txt_f="11571">p</offsets></italic><offsets xml_i="24947" xml_f="25041" txt_i="11571" txt_f="11665"> = 0.87), but more men in the ProtecT group received RT compared to the matched ACN controls (</offsets><italic><offsets xml_i="25049" xml_f="25050" txt_i="11665" txt_f="11666">p</offsets></italic><offsets xml_i="25059" xml_f="25073" txt_i="11666" txt_f="11677"> &lt; 0.0001; </offsets><xref rid="tbl0010" ref-type="table"><offsets xml_i="25110" xml_f="25117" txt_i="11677" txt_f="11684">Table 2</offsets></xref><offsets xml_i="25124" xml_f="25126" txt_i="11684" txt_f="11686">).</offsets></p><p><offsets xml_i="25133" xml_f="25205" txt_i="11687" txt_f="11759">Among the ProtecT matched cases, 247 men received radical treatment (RP </offsets><italic><offsets xml_i="25213" xml_f="25214" txt_i="11759" txt_f="11760">n</offsets></italic><offsets xml_i="25223" xml_f="25233" txt_i="11760" txt_f="11770"> = 47; RT </offsets><italic><offsets xml_i="25241" xml_f="25242" txt_i="11770" txt_f="11771">n</offsets></italic><offsets xml_i="25251" xml_f="25288" txt_i="11771" txt_f="11808"> = 200) of whom 12 died from PCa (RP </offsets><italic><offsets xml_i="25296" xml_f="25297" txt_i="11808" txt_f="11809">n</offsets></italic><offsets xml_i="25306" xml_f="25320" txt_i="11809" txt_f="11823"> = 1 [4%]; RT </offsets><italic><offsets xml_i="25328" xml_f="25329" txt_i="11823" txt_f="11824">n</offsets></italic><offsets xml_i="25338" xml_f="25380" txt_i="11824" txt_f="11866"> = 11 [6%]) and 33 died of all causes [RP </offsets><italic><offsets xml_i="25388" xml_f="25389" txt_i="11866" txt_f="11867">n</offsets></italic><offsets xml_i="25398" xml_f="25412" txt_i="11867" txt_f="11881"> = 2 [4%]; RT </offsets><italic><offsets xml_i="25420" xml_f="25421" txt_i="11881" txt_f="11882">n</offsets></italic><offsets xml_i="25430" xml_f="25443" txt_i="11882" txt_f="11895"> = 31 [16%]).</offsets></p><p><offsets xml_i="25450" xml_f="25521" txt_i="11896" txt_f="11967">Among the ACN matched controls, 277 men received radical treatment (RP </offsets><italic><offsets xml_i="25529" xml_f="25530" txt_i="11967" txt_f="11968">n</offsets></italic><offsets xml_i="25539" xml_f="25550" txt_i="11968" txt_f="11979"> = 150; RT </offsets><italic><offsets xml_i="25558" xml_f="25559" txt_i="11979" txt_f="11980">n</offsets></italic><offsets xml_i="25568" xml_f="25603" txt_i="11980" txt_f="12015"> = 127) of whom 11 died of PCa (RP </offsets><italic><offsets xml_i="25611" xml_f="25612" txt_i="12015" txt_f="12016">n</offsets></italic><offsets xml_i="25621" xml_f="25635" txt_i="12016" txt_f="12030"> = 5 [3%]; RT </offsets><italic><offsets xml_i="25643" xml_f="25644" txt_i="12030" txt_f="12031">n</offsets></italic><offsets xml_i="25653" xml_f="25694" txt_i="12031" txt_f="12072"> = 6 [5%]) and 32 died of all causes (RP </offsets><italic><offsets xml_i="25702" xml_f="25703" txt_i="12072" txt_f="12073">n</offsets></italic><offsets xml_i="25712" xml_f="25727" txt_i="12073" txt_f="12088"> = 12 [8%]; RT </offsets><italic><offsets xml_i="25735" xml_f="25736" txt_i="12088" txt_f="12089">n</offsets></italic><offsets xml_i="25745" xml_f="25758" txt_i="12089" txt_f="12102"> = 20 [16%]).</offsets></p><p><offsets xml_i="25765" xml_f="25888" txt_i="12103" txt_f="12226">Among the matched men who received nonradical treatment, a significantly greater proportion died in the ACN control group (</offsets><italic><offsets xml_i="25896" xml_f="25897" txt_i="12226" txt_f="12227">n</offsets></italic><offsets xml_i="25906" xml_f="25980" txt_i="12227" txt_f="12301"> = 114; 51 PCa deaths and 68 all-cause deaths) than in the ProtecT group (</offsets><italic><offsets xml_i="25988" xml_f="25989" txt_i="12301" txt_f="12302">n</offsets></italic><offsets xml_i="25998" xml_f="26045" txt_i="12302" txt_f="12349"> = 105; 19 PCa deaths and 37 all-cause deaths; </offsets><italic><offsets xml_i="26053" xml_f="26054" txt_i="12349" txt_f="12350">p</offsets></italic><offsets xml_i="26063" xml_f="26077" txt_i="12350" txt_f="12361"> &lt; 0.0002; </offsets><xref rid="tbl0010" ref-type="table"><offsets xml_i="26114" xml_f="26121" txt_i="12361" txt_f="12368">Table 2</offsets></xref><offsets xml_i="26128" xml_f="26130" txt_i="12368" txt_f="12370">).</offsets></p></sec><sec id="sec0055"><label><offsets xml_i="26165" xml_f="26170" txt_i="12372" txt_f="12377">3.2.3</offsets></label><title><offsets xml_i="26185" xml_f="26257" txt_i="12377" txt_f="12449">Comparison with ACN controls: Cox proportional hazards survival analysis</offsets></title><p><offsets xml_i="26268" xml_f="26345" txt_i="12450" txt_f="12527">Multivariable analysis for the unmatched groups revealed that ProtecT cases (</offsets><italic><offsets xml_i="26353" xml_f="26354" txt_i="12527" txt_f="12528">n</offsets></italic><offsets xml_i="26363" xml_f="26438" txt_i="12528" txt_f="12603"> = 404) had a 53% lower risk of death from PCa (HR 0.47, 95% CI 0.34–0.66; </offsets><italic><offsets xml_i="26446" xml_f="26447" txt_i="12603" txt_f="12604">p</offsets></italic><offsets xml_i="26456" xml_f="26544" txt_i="12604" txt_f="12689"> &lt; 0.0001) and a 30% lower risk of death from all causes (HR 0.70, 95% CI 0.56–0.88; </offsets><italic><offsets xml_i="26552" xml_f="26553" txt_i="12689" txt_f="12690">p</offsets></italic><offsets xml_i="26562" xml_f="26612" txt_i="12690" txt_f="12737"> &lt; 0.0001) compared to unmatched ACN controls (</offsets><italic><offsets xml_i="26620" xml_f="26621" txt_i="12737" txt_f="12738">n</offsets></italic><offsets xml_i="26630" xml_f="26639" txt_i="12738" txt_f="12747"> = 3335; </offsets><xref rid="tbl0015" ref-type="table"><offsets xml_i="26676" xml_f="26683" txt_i="12747" txt_f="12754">Table 3</offsets></xref><offsets xml_i="26690" xml_f="27061" txt_i="12754" txt_f="13125">). Higher PSA, higher Gleason score, and higher stage all indicated a greater risk of death, whereas later years of diagnosis lowered the risk. There was also a higher risk of death from all causes in the oldest age group (67–72 yr). A subset analysis for men with N0, M0 disease did not demonstrate a difference in the risk of death from PCa (HR 0.69, 95% CI 0.45–1.06; </offsets><italic><offsets xml_i="27069" xml_f="27070" txt_i="13125" txt_f="13126">p</offsets></italic><offsets xml_i="27079" xml_f="27130" txt_i="13126" txt_f="13177"> = 0.09) or all causes (HR 0.94, 95% CI 0.73–1.22; </offsets><italic><offsets xml_i="27138" xml_f="27139" txt_i="13177" txt_f="13178">p</offsets></italic><offsets xml_i="27148" xml_f="27290" txt_i="13178" txt_f="13320"> = 0.65) between the unmatched groups. However, men with N1 or M1 disease had a much lower risk of death from PCa (HR 0.33, 95% CI 0.18–0.59; </offsets><italic><offsets xml_i="27298" xml_f="27299" txt_i="13320" txt_f="13321">p</offsets></italic><offsets xml_i="27308" xml_f="27442" txt_i="13321" txt_f="13449"> &lt; 0.0001) and all causes (HR 0.38; 0.22 - 0.63; P &lt; 0.0001) in the ProtecT group than in the ACN group (Supplementary Table 2).</offsets></p><p><offsets xml_i="27449" xml_f="27697" txt_i="13450" txt_f="13698">Multivariable analysis was performed for the matched groups after further adjusting for treatment received. We did not find evidence of a difference in the risk of death from PCa among men who received radical treatment (HR 1.91, 95% CI 0.73–5.02; </offsets><italic><offsets xml_i="27705" xml_f="27706" txt_i="13698" txt_f="13699">p</offsets></italic><offsets xml_i="27715" xml_f="27841" txt_i="13699" txt_f="13825"> = 0.19). Men treated with RT had a higher risk of death from all causes compared to the RP group (HR 2.02, 95% CI 1.08–3.77, </offsets><italic><offsets xml_i="27849" xml_f="27850" txt_i="13825" txt_f="13826">p</offsets></italic><offsets xml_i="27859" xml_f="27944" txt_i="13826" txt_f="13911"> = 0.03). There was a much higher risk of death from PCa (HR 6.70, 95% CI 2.64–16.9; </offsets><italic><offsets xml_i="27952" xml_f="27953" txt_i="13911" txt_f="13912">p</offsets></italic><offsets xml_i="27962" xml_f="28019" txt_i="13912" txt_f="13966"> &lt; 0.0001) and all causes (HR 4.55, 95% CI 2.42–8.52; </offsets><italic><offsets xml_i="28027" xml_f="28028" txt_i="13966" txt_f="13967">p</offsets></italic><offsets xml_i="28037" xml_f="28169" txt_i="13967" txt_f="14096"> &lt; 0.0001) among men who received nonradical treatment compared to those who underwent radical treatment (Supplementary Table 3).</offsets></p></sec><sec id="sec0060"><label><offsets xml_i="28204" xml_f="28209" txt_i="14098" txt_f="14103">3.2.4</offsets></label><title><offsets xml_i="28224" xml_f="28319" txt_i="14103" txt_f="14198">Kaplan-Meier analysis of biochemical recurrence by primary treatment group in the ProtecT group</offsets></title><p><offsets xml_i="28330" xml_f="28825" txt_i="14199" txt_f="14694">PSA follow-up was available for ProtecT cases and is reported in more detail in the Supplementary material. At a median of 7.4 yr, PCa-specific survival was 96% in the RP group and 96% in the RT group. There were no predictors of biochemical failure, PCa-specific mortality, or overall mortality among men treated with RP or RT on univariable or multivariable analysis, except for high Gleason score, which increased the risk of death from all causes in the RT group (HR 6.48, 95% CI 1.48–28.4; </offsets><italic><offsets xml_i="28833" xml_f="28834" txt_i="14694" txt_f="14695">p</offsets></italic><offsets xml_i="28843" xml_f="28900" txt_i="14695" txt_f="14752"> = 0.01; Supplementary Table 4 and Supplementary Fig. 2).</offsets></p></sec></sec></sec><sec id="sec0065"><label><offsets xml_i="28947" xml_f="28948" txt_i="14756" txt_f="14757">4</offsets></label><title><offsets xml_i="28963" xml_f="28973" txt_i="14757" txt_f="14767">Discussion</offsets></title><p><offsets xml_i="28984" xml_f="29706" txt_i="14768" txt_f="15490">This study reports on asymptomatic men who were excluded from ProtecT because of advanced and high-risk PCa; their outcomes form an important component of the overall context of the ProtecT study and its generalisability with respect to treatment of PSA-detected PCa. In men who were excluded from ProtecT, but were treated radically, we found low rates of all-cause and PCa specific deaths (14% and 5%), with no differences between surgery and radiotherapy at a median of 7.4 years. Most deaths occurred among men receiving nonradical treatments, probably because they had more advanced disease and/or were not fit for radical treatment, although very unfit men were screened out from ProtecT by the general practitioner.</offsets></p><p><offsets xml_i="29713" xml_f="29823" txt_i="15491" txt_f="15601">With respect to the main clinical outcome paper from ProtecT, all-cause mortality (∼10% at a median of 10 yr) </offsets><xref rid="bib0190" ref-type="bibr"><offsets xml_i="29859" xml_f="29863" txt_i="15601" txt_f="15605">[13]</offsets></xref><offsets xml_i="29870" xml_f="30471" txt_i="15605" txt_f="16206"> was lower than that noted here in the RT group (15%). This suggests that ProtecT men with advanced PCa treated by RT in the present study were less fit than those in the randomised group. Moreover, the group who received nonradical treatment and those whose treatment was unknown had significantly greater all-cause mortality (38% and 42%, respectively) compared with those undergoing radical treatment. The PCa-specific mortality among the ProtecT group receiving radical treatment (5%) was greater than that found in the randomised group (∼1%), but nevertheless indicates very good cancer survival.</offsets></p><p><offsets xml_i="30478" xml_f="30935" txt_i="16207" txt_f="16664">The reduction in risk of death from PCa among advanced ProtecT cases (45%) compared to ACN controls persisted after careful case-control matching to attempt to compensate for leadtime bias and differences in baseline characteristics. However, other biases cannot be ruled out, including the greater number of men undergoing surgery in the ACN group than in the ProtecT group when comparing those who received radical treatment, and the fact that the ACN gro</offsets></p><p><offsets xml_i="30942" xml_f="31159" txt_i="16665" txt_f="16882">Cox regression results for survival analysis (53% lower risk of death from PCa and a 30% reduction in all-cause mortality in the ProtecT group) can probably be explained in part by leadtime bias in the ProtecT cohort </offsets><xref rid="bib0215" ref-type="bibr"><offsets xml_i="31195" xml_f="31199" txt_i="16882" txt_f="16886">[18]</offsets></xref><offsets xml_i="31206" xml_f="31208" txt_i="16886" txt_f="16888">, </offsets><xref rid="bib0220" ref-type="bibr"><offsets xml_i="31244" xml_f="31248" txt_i="16888" txt_f="16892">[19]</offsets></xref><offsets xml_i="31255" xml_f="31256" txt_i="16892" txt_f="16893">.</offsets></p><p><offsets xml_i="31263" xml_f="31582" txt_i="16894" txt_f="17213">We found no difference in PCa-specific or overall survival between the RP and RT ProtecT groups. Only a small proportion of men who received radical treatment (RP 4%, RT 5%) died from PCa, which adds to increasing evidence that radical treatment of locally advanced or high-risk disease delivers good oncologic outcomes</offsets><xref rid="bib0165" ref-type="bibr"><offsets xml_i="31618" xml_f="31621" txt_i="17213" txt_f="17216">[8]</offsets></xref><offsets xml_i="31628" xml_f="31630" txt_i="17216" txt_f="17218">, </offsets><xref rid="bib0170" ref-type="bibr"><offsets xml_i="31666" xml_f="31669" txt_i="17218" txt_f="17221">[9]</offsets></xref><offsets xml_i="31676" xml_f="31823" txt_i="17221" txt_f="17368">. The all-cause and PCa survival outcomes for the ProtecT group are better than in most studies on men clinically presenting with advanced disease </offsets><xref rid="bib0225" ref-type="bibr"><offsets xml_i="31859" xml_f="31863" txt_i="17368" txt_f="17372">[20]</offsets></xref><offsets xml_i="31870" xml_f="32143" txt_i="17372" txt_f="17645">, supporting the hypothesis that early detection of advanced and high-risk PCa may be of benefit. The wider context of the impact of PSA testing on community-based men will be presented in the findings of the CAP (Cluster randomised trial of prostate cancer) trial in 2017 </offsets><xref rid="bib0230" ref-type="bibr"><offsets xml_i="32179" xml_f="32183" txt_i="17645" txt_f="17649">[21]</offsets></xref><offsets xml_i="32190" xml_f="32191" txt_i="17649" txt_f="17650">.</offsets></p><p><offsets xml_i="32198" xml_f="32257" txt_i="17651" txt_f="17710">The quality of data for the ACN group is likely to be good </offsets><xref rid="bib0200" ref-type="bibr"><offsets xml_i="32293" xml_f="32297" txt_i="17710" txt_f="17714">[15]</offsets></xref><offsets xml_i="32304" xml_f="32306" txt_i="17714" txt_f="17716">, </offsets><xref rid="bib0230" ref-type="bibr"><offsets xml_i="32342" xml_f="32346" txt_i="17716" txt_f="17720">[21]</offsets></xref><offsets xml_i="32353" xml_f="32594" txt_i="17720" txt_f="17961">. We minimised misattribution of death by using two independent clinicians blinded to the study group and treatment, and by checking with the ProtecT recruitment centre of origin. Matching reduced the number of men for the matched analysis (</offsets><italic><offsets xml_i="32602" xml_f="32603" txt_i="17961" txt_f="17962">n</offsets></italic><offsets xml_i="32612" xml_f="32863" txt_i="17962" txt_f="18213"> = 401) and there may be additional biases that our matching process was unable to take into account. Multidisciplinary teams reviewed the histopathology for ACN controls, whereas ProtecT cases were reviewed by the expert ProtecT histopathology group </offsets><xref rid="bib0235" ref-type="bibr"><offsets xml_i="32899" xml_f="32903" txt_i="18213" txt_f="18217">[22]</offsets></xref><offsets xml_i="32910" xml_f="33597" txt_i="18217" txt_f="18904">. For surgically treated ACN cases, however, histology was reviewed centrally. Potential differences in grade and stage allocation may have had some impact on apparent survival benefits among the ProtecT cases. There was no information available on the comorbidity burden for the ACN controls, and therefore we were unable to match the two groups according to these factors. ProtecT participants were 98% Caucasian and patients with a prior history of cancer were excluded, which may have influenced overall survival. The natural history of PCa can be long and further follow-up is required, but such leadtime factors are likely to be of lesser magnitude among men with advanced disease </offsets><xref rid="bib0240" ref-type="bibr"><offsets xml_i="33633" xml_f="33637" txt_i="18904" txt_f="18908">[23]</offsets></xref><offsets xml_i="33644" xml_f="33646" txt_i="18908" txt_f="18910">, </offsets><xref rid="bib0245" ref-type="bibr"><offsets xml_i="33682" xml_f="33686" txt_i="18910" txt_f="18914">[24]</offsets></xref><offsets xml_i="33693" xml_f="33695" txt_i="18914" txt_f="18916">, </offsets><xref rid="bib0250" ref-type="bibr"><offsets xml_i="33731" xml_f="33735" txt_i="18916" txt_f="18920">[25]</offsets></xref><offsets xml_i="33742" xml_f="33743" txt_i="18920" txt_f="18921">.</offsets></p></sec><sec id="sec0070"><label><offsets xml_i="33778" xml_f="33779" txt_i="18923" txt_f="18924">5</offsets></label><title><offsets xml_i="33794" xml_f="33805" txt_i="18924" txt_f="18935">Conclusions</offsets></title><p><offsets xml_i="33816" xml_f="34307" txt_i="18936" txt_f="19427">PSA testing identifies asymptomatic men with advanced and high-risk PCa whose early treatment leads to good survival rates. We observed improved survival in the ProtecT men who received nonradical treatment compared to men presenting clinically without PSA testing, although leadtime and selection bias are difficult to exclude. It will be important to assess longer-term survival and add patient-reported outcomes among these men to assess the balance between treatment impact and survival.</offsets></p><p><offsets xml_i="34314" xml_f="34316" txt_i="19428" txt_f="19430">  </offsets><italic><bold><offsets xml_i="34330" xml_f="34351" txt_i="19430" txt_f="19451">Author contributions:</offsets></bold></italic><offsets xml_i="34367" xml_f="34525" txt_i="19451" txt_f="19609"> Alastair D. Lamb had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.  </offsets></p><p><italic><offsets xml_i="34540" xml_f="34565" txt_i="19610" txt_f="19635">Study concept and design:</offsets></italic><offsets xml_i="34574" xml_f="34602" txt_i="19635" txt_f="19663"> Neal, Hamdy, Donovan, Lane.</offsets></p><p><italic><offsets xml_i="34617" xml_f="34637" txt_i="19664" txt_f="19684">Acquisition of data:</offsets></italic><offsets xml_i="34646" xml_f="34704" txt_i="19684" txt_f="19742"> Xiong, Johnston, Shaw, Lamb, Neal, Hamdy, Donovan, Davis.</offsets></p><p><italic><offsets xml_i="34719" xml_f="34755" txt_i="19743" txt_f="19779">Analysis and interpretation of data:</offsets></italic><offsets xml_i="34764" xml_f="34803" txt_i="19779" txt_f="19818"> Johnston, Parashar, Shaw, Lamb, Xiong.</offsets></p><p><italic><offsets xml_i="34818" xml_f="34845" txt_i="19819" txt_f="19846">Drafting of the manuscript:</offsets></italic><offsets xml_i="34854" xml_f="34876" txt_i="19846" txt_f="19868"> Johnston, Lamb, Neal.</offsets></p><p><italic><offsets xml_i="34891" xml_f="34962" txt_i="19869" txt_f="19940">Critical revision of the manuscript for important intellectual content:</offsets></italic><offsets xml_i="34971" xml_f="35009" txt_i="19940" txt_f="19978"> Johnston, Lamb, Neal, Hamdy, Donovan.</offsets></p><p><italic><offsets xml_i="35024" xml_f="35045" txt_i="19979" txt_f="20000">Statistical analysis:</offsets></italic><offsets xml_i="35054" xml_f="35074" txt_i="20000" txt_f="20020"> Johnston, Parashar.</offsets></p><p><italic><offsets xml_i="35089" xml_f="35107" txt_i="20021" txt_f="20039">Obtaining funding:</offsets></italic><offsets xml_i="35116" xml_f="35138" txt_i="20039" txt_f="20061"> Neal, Hamdy, Donovan.</offsets></p><p><italic><offsets xml_i="35153" xml_f="35200" txt_i="20062" txt_f="20109">Administrative, technical, or material support:</offsets></italic><offsets xml_i="35209" xml_f="35215" txt_i="20109" txt_f="20115"> None.</offsets></p><p><italic><offsets xml_i="35230" xml_f="35242" txt_i="20116" txt_f="20128">Supervision:</offsets></italic><offsets xml_i="35251" xml_f="35273" txt_i="20128" txt_f="20150"> Neal, Hamdy, Donovan.</offsets></p><p><italic><offsets xml_i="35288" xml_f="35317" txt_i="20151" txt_f="20180">Other (review of manuscript):</offsets></italic><offsets xml_i="35326" xml_f="35341" txt_i="20180" txt_f="20195"> All authors.  </offsets></p><p><italic><bold><offsets xml_i="35362" xml_f="35384" txt_i="20196" txt_f="20218">Financial disclosures:</offsets></bold></italic><offsets xml_i="35400" xml_f="35804" txt_i="20218" txt_f="20622"> Alastair D. Lamb certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.  </offsets></p><p><italic><bold><offsets xml_i="35825" xml_f="35865" txt_i="20623" txt_f="20663">Funding/Support and role of the sponsor:</offsets></bold></italic><offsets xml_i="35881" xml_f="36077" txt_i="20663" txt_f="20859"> The ProtecT trial is funded by the UK National Institute for Health Research (NIHR) Health Technology Assessment Programme (projects 96/20/06, 96/20/99) with the University of Oxford as sponsor (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.nets.nihr.ac.uk/projects/hta/962099" id="intr0005"><offsets xml_i="36181" xml_f="36220" txt_i="20859" txt_f="20898">www.nets.nihr.ac.uk/projects/hta/962099</offsets></ext-link><offsets xml_i="36231" xml_f="36635" txt_i="20898" txt_f="21302">). The sponsor played a role in the design and conduct of the study. Jenny L. Donovan is supported by the NIHR Collaboration for Leadership in Applied Health Research and Care West, hosted by University Hospitals Bristol NHS Foundation Trust. Freddie C. Hamdy is supported by the Oxford NIHR Biomedical Research Centre Surgical Innovation and Evaluation Theme, and the Cancer Research UK Oxford Centre.  </offsets></p><p><italic><bold><offsets xml_i="36656" xml_f="36672" txt_i="21303" txt_f="21319">Acknowledgments:</offsets></bold></italic><offsets xml_i="36688" xml_f="37205" txt_i="21319" txt_f="21836"> The authors wish to acknowledge the tremendous contribution of all the ProtecT study participants, researchers, data monitoring committee (Chairs: Professors Adrian Grant and Ian Roberts; Prof. Deborah Ashby, Dr. Richard Cowan, Prof. Peter Fayers, Prof. Killian Mellon, Prof. James N’Dow, Mr. Tim O’Brien, Dr. Michael Sokal), and trial steering committee (Chair: Prof. Michael Baum; Prof. Anthony Zietman, Prof. David Dearnaley, Dr. Jan Adolfsson, Prof. Peter Albertsen, Prof. Fritz Schröder, Prof. Tracy Roberts).  </offsets></p><p><italic><bold><offsets xml_i="37226" xml_f="37258" txt_i="21837" txt_f="21869">Department of Health disclaimer:</offsets></bold></italic><offsets xml_i="37274" xml_f="37405" txt_i="21869" txt_f="22000"> The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Department of Health.</offsets></p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0130"><label>1</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Schröder</surname><given-names>F.H.</given-names></name><name><surname>Hugosson</surname><given-names>J.</given-names></name><name><surname>Roobol</surname><given-names>M.J.</given-names></name></person-group><article-title>Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up</article-title><source>Lancet</source><volume>384</volume><year>2014</year><fpage>2027</fpage><lpage>2035</lpage><pub-id pub-id-type="pmid">25108889</pub-id></element-citation></ref><ref id="bib0135"><label>2</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name><surname>Andriole</surname><given-names>G.L.</given-names></name><name><surname>Crawford</surname><given-names>E.D.</given-names></name><name><surname>Grubb</surname><given-names>R.L.</given-names><suffix>3rd</suffix></name></person-group><article-title>Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up</article-title><source>J Natl Cancer Inst</source><volume>104</volume><year>2012</year><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">22228146</pub-id></element-citation></ref><ref id="bib0140"><label>3</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name><surname>Shoag</surname><given-names>J.E.</given-names></name><name><surname>Mittal</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>J.C.</given-names></name></person-group><article-title>Reevaluating PSA testing rates in the PLCO trial</article-title><source>N Engl J Med</source><volume>374</volume><year>2016</year><fpage>1795</fpage><lpage>1796</lpage><pub-id pub-id-type="pmid">27144870</pub-id></element-citation></ref><ref id="bib0145"><label>4</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name><surname>Wilt</surname><given-names>T.J.</given-names></name><name><surname>Brawer</surname><given-names>M.K.</given-names></name><name><surname>Jones</surname><given-names>K.M.</given-names></name></person-group><article-title>Radical prostatectomy versus observation for localized prostate cancer</article-title><source>N Engl J Med</source><volume>367</volume><year>2012</year><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">22808955</pub-id></element-citation></ref><ref id="bib0150"><label>5</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name><surname>Widmark</surname><given-names>A.</given-names></name><name><surname>Klepp</surname><given-names>O.</given-names></name><name><surname>Solberg</surname><given-names>A.</given-names></name></person-group><article-title>Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial</article-title><source>Lancet</source><volume>373</volume><year>2009</year><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">19091394</pub-id></element-citation></ref><ref id="bib0155"><label>6</label><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name><surname>Warde</surname><given-names>P.</given-names></name><name><surname>Mason</surname><given-names>M.</given-names></name><name><surname>Ding</surname><given-names>K.</given-names></name></person-group><article-title>Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial</article-title><source>Lancet</source><volume>378</volume><year>2011</year><fpage>2104</fpage><lpage>2111</lpage><pub-id pub-id-type="pmid">22056152</pub-id></element-citation></ref><ref id="bib0160"><label>7</label><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name><surname>Abdollah</surname><given-names>F.</given-names></name><name><surname>Sun</surname><given-names>M.</given-names></name><name><surname>Thuret</surname><given-names>R.</given-names></name></person-group><article-title>A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988-2006</article-title><source>Eur Urol</source><volume>59</volume><year>2011</year><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">20965646</pub-id></element-citation></ref><ref id="bib0165"><label>8</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name><surname>Boorjian</surname><given-names>S.A.</given-names></name><name><surname>Karnes</surname><given-names>R.J.</given-names></name><name><surname>Viterbo</surname><given-names>R.</given-names></name></person-group><article-title>Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer</article-title><source>Cancer</source><volume>117</volume><year>2011</year><fpage>2883</fpage><lpage>2891</lpage><pub-id pub-id-type="pmid">21692049</pub-id></element-citation></ref><ref id="bib0170"><label>9</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name><surname>Sooriakumaran</surname><given-names>P.</given-names></name><name><surname>Nyberg</surname><given-names>T.</given-names></name><name><surname>Akre</surname><given-names>O.</given-names></name></person-group><article-title>Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes</article-title><source>Br Med J</source><volume>348</volume><year>2014</year><fpage>1502</fpage><lpage>1515</lpage></element-citation></ref><ref id="bib0175"><label>10</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>D.C.</given-names></name><name><surname>Lophatananon</surname><given-names>A.</given-names></name><name><surname>Wright</surname><given-names>K.A.</given-names></name><name><surname>Muir</surname><given-names>K.R.</given-names></name><name><surname>Gnanapragasam</surname><given-names>V.J.</given-names></name></person-group><article-title>Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population</article-title><source>PLoS One</source><volume>10</volume><year>2015</year><fpage>e0119494</fpage><pub-id pub-id-type="pmid">25742020</pub-id></element-citation></ref><ref id="bib0180"><label>11</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name><surname>Donovan</surname><given-names>J.</given-names></name><name><surname>Hamdy</surname><given-names>F.</given-names></name><name><surname>Neal</surname><given-names>D.</given-names></name><name><surname>Peters</surname><given-names>T.</given-names></name><name><surname>Oliver</surname><given-names>S.</given-names></name></person-group><article-title>Prostate Testing for Cancer and Treatment (ProtecT) feasibility study</article-title><source>Health Technol Assess</source><volume>7</volume><year>2003</year><fpage>42</fpage></element-citation></ref><ref id="bib0185"><label>12</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>J.A.</given-names></name><name><surname>Donovan</surname><given-names>J.L.</given-names></name><name><surname>Davis</surname><given-names>M.</given-names></name></person-group><article-title>Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial</article-title><source>Lancet Oncol</source><volume>15</volume><year>2014</year><fpage>1109</fpage><lpage>1118</lpage><pub-id pub-id-type="pmid">25163905</pub-id></element-citation></ref><ref id="bib0190"><label>13</label><mixed-citation publication-type="other" id="oref0065">Hamdy FC Donovan JL, Athene JL, et al. Prostate cancer mortality and outcomes at 10 year follow-up in the ProtecT trial. N Engl J Med. <ext-link ext-link-type="doi" xlink:href="10.1056/NEJMoa1606220" id="intr0015">http://dx.doi.org/10.1056/NEJMoa1606220</ext-link></mixed-citation></ref><ref id="bib0195"><label>14</label><mixed-citation publication-type="other" id="oref0070">Donovan JL, Hamdy FC, Lane AJ, et al. Patient reported outcomes over six years in the ProtecT prostate cancer trial. N Engl J Med. <ext-link ext-link-type="doi" xlink:href="10.1056/NEJMoa1696221" id="intr0020">http://dx.doi.org/10.1056/NEJMoa1696221</ext-link></mixed-citation></ref><ref id="bib0200"><label>15</label><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>D.C.</given-names></name><name><surname>Wright</surname><given-names>K.A.</given-names></name><name><surname>Lophathanon</surname><given-names>A.</given-names></name><name><surname>Muir</surname><given-names>K.R.</given-names></name><name><surname>Gnanapragasam</surname><given-names>V.J.</given-names></name></person-group><article-title>Changing presentation of prostate cancer in a UK population — 10 year trends in prostate cancer risk profiles in the East of England</article-title><source>Br J Cancer</source><volume>109</volume><year>2013</year><fpage>2115</fpage><lpage>2120</lpage><pub-id pub-id-type="pmid">24071596</pub-id></element-citation></ref><ref id="bib0205"><label>16</label><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name><surname>Melia</surname><given-names>J.</given-names></name><name><surname>Moss</surname><given-names>S.</given-names></name><name><surname>Johns</surname><given-names>L.</given-names></name></person-group><article-title>Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study</article-title><source>BJU Int</source><volume>94</volume><year>2004</year><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">15217430</pub-id></element-citation></ref><ref id="bib0210"><label>17</label><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>N.</given-names></name><name><surname>Hughes</surname><given-names>L.J.</given-names></name><name><surname>Turner</surname><given-names>E.L.</given-names></name></person-group><article-title>Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities</article-title><source>BJU Int</source><volume>108</volume><year>2011</year><fpage>1402</fpage><lpage>1408</lpage><pub-id pub-id-type="pmid">21481132</pub-id></element-citation></ref><ref id="bib0215"><label>18</label><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>A.L.</given-names></name><name><surname>Dimitropoulou</surname><given-names>P.</given-names></name><name><surname>Lane</surname><given-names>A.</given-names></name></person-group><article-title>Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer</article-title><source>BJU Int</source><volume>104</volume><year>2009</year><fpage>1592</fpage><lpage>1598</lpage><pub-id pub-id-type="pmid">19549125</pub-id></element-citation></ref><ref id="bib0220"><label>19</label><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name><surname>Collin</surname><given-names>S.M.</given-names></name><name><surname>Martin</surname><given-names>R.M.</given-names></name><name><surname>Metcalfe</surname><given-names>C.</given-names></name></person-group><article-title>Prostate-cancer mortality in the USA and UK in 1975 to 2004: an ecological study</article-title><source>Lancet Oncol</source><volume>9</volume><year>2008</year><fpage>445</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">18424233</pub-id></element-citation></ref><ref id="bib0225"><label>20</label><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>M.D.</given-names></name><name><surname>Parulekar</surname><given-names>W.R.</given-names></name><name><surname>Sydes</surname><given-names>M.R.</given-names></name></person-group><article-title>Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer</article-title><source>J Clin Oncol</source><volume>33</volume><year>2015</year><fpage>2143</fpage><lpage>2150</lpage><pub-id pub-id-type="pmid">25691677</pub-id></element-citation></ref><ref id="bib0230"><label>21</label><mixed-citation publication-type="other" id="oref0105">UK Department of Health. Delivering the cancer reform strategy. Report by the Controller and Auditor General. London, UK: National Audit Office; 2010. www.nao.org.uk/wp-content/uploads/2010/11/1011568.pdf.</mixed-citation></ref><ref id="bib0235"><label>22</label><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name><surname>Oxley</surname><given-names>J.</given-names></name><name><surname>Simpkin</surname><given-names>A.</given-names></name><name><surname>Goepel</surname><given-names>J.</given-names></name></person-group><article-title>Gleason drift in the NIHR ProtecT study</article-title><source>Histopathology</source><volume>66</volume><year>2015</year><fpage>438</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">25231130</pub-id></element-citation></ref><ref id="bib0240"><label>23</label><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name><surname>Albertsen</surname><given-names>P.C.</given-names></name><name><surname>Hanley</surname><given-names>J.A.</given-names></name><name><surname>Fine</surname><given-names>J.</given-names></name></person-group><article-title>20-year outcomes following conservative management of clinically localized prostate cancer</article-title><source>JAMA</source><volume>293</volume><year>2005</year><fpage>2095</fpage><lpage>2101</lpage><pub-id pub-id-type="pmid">15870412</pub-id></element-citation></ref><ref id="bib0245"><label>24</label><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name><surname>Bill-Axelson</surname><given-names>A.</given-names></name><name><surname>Holmberg</surname><given-names>L.</given-names></name><name><surname>Ruutu</surname><given-names>M.</given-names></name></person-group><article-title>Radical prostatectomy versus watchful waiting in early prostate cancer</article-title><source>N Engl J Med</source><volume>352</volume><year>2005</year><fpage>1977</fpage><lpage>1984</lpage><pub-id pub-id-type="pmid">15888698</pub-id></element-citation></ref><ref id="bib0250"><label>25</label><element-citation publication-type="journal" id="sbref0250"><person-group person-group-type="author"><name><surname>Bill-Axelson</surname><given-names>A.</given-names></name><name><surname>Holmberg</surname><given-names>L.</given-names></name><name><surname>Filen</surname><given-names>F.</given-names></name></person-group><article-title>Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial</article-title><source>J Natl Cancer Inst</source><volume>100</volume><year>2008</year><fpage>1144</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">18695132</pub-id></element-citation></ref></ref-list><sec id="sec0085" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p><supplementary-material content-type="local-data" id="upi0005"><media xlink:href="mmc1.docx"></media></supplementary-material></p></sec><fn-group><fn id="sec0080" fn-type="supplementary-material"><label>Appendix A</label><p>Supplementary data associated with this article can be found, in the online version, at <ext-link ext-link-type="doi" xlink:href="10.1016/j.eururo.2016.09.040" id="intr0010">http://dx.doi.org/10.1016/j.eururo.2016.09.040</ext-link>.</p></fn></fn-group></back><floats-group><fig id="fig0005"><label>Fig. 1</label><caption><p>Diagram of patient flow through study. KM = Kaplan-Meier; PSA = prostate-specific antigen.</p></caption><graphic xlink:href="gr1"></graphic></fig><fig id="fig0010"><label>Fig. 2</label><caption><p>(A) Prostate cancer–specific survival and (B) overall survival according to primary treatment groups among ProtecT cases. Death from prostate cancer occurred in two (4%) of the RP and 12 (5%) of the RT group (HR 0.95, CI 95% 0.22–4.12; <italic>p</italic> = 0.94). Death from all causes occurred in four (7%) of the RP and 37 (15%) of the RT group (HR 0.69, 95% CI 0.29–1.67; <italic>p</italic> = 0.41). A significantly greater proportion of the ADT group died from prostate cancer (<italic>n</italic> = 27, 22%) and all causes (<italic>n</italic> = 49, 40%) compared to men treated with radical therapy (<italic>p</italic> &lt; 0.0001). RP = radical prostatectomy; RT = radical radiotherapy; ADT = androgen deprivation therapy; HR = hazard ratio; CI = confidence interval.</p></caption><graphic xlink:href="gr2"></graphic></fig><fig id="fig0015"><label>Fig. 3</label><caption><p>Kaplan-Meier plots of (A) prostate cancer–specific survival and (B) overall survival among matched ProtecT cases and Anglia Cancer Network (ACN) controls. By the end of the study, 37 matched cases (9%) and 64 controls (16%) died from prostate cancer. Death from all causes occurred in 89 cases (22%) and 103 controls (26%). HR = hazard ratio; CI = confidence interval.</p></caption><graphic xlink:href="gr3"></graphic></fig><table-wrap id="tbl0005" position="float"><label>Table 1</label><caption><p>Demographic and clinicopathologic data for the study cohort</p></caption><alt-text id="at1">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th colspan="3" align="center">Unmatched<hr></hr></th><th colspan="3" align="center">Matched<hr></hr></th></tr><tr><th></th><th align="center">ProtecT</th><th align="center">ACN</th><th align="center"><italic>p</italic> value <xref rid="tblfn0005" ref-type="table-fn">a</xref></th><th align="center">ProtecT</th><th align="center">ACN</th><th align="center"><italic>p</italic> value <xref rid="tblfn0005" ref-type="table-fn">a</xref></th></tr></thead><tbody><tr><td align="left">Patients (<italic>n</italic>)</td><td align="char">492</td><td align="char">3978</td><td></td><td align="char">401</td><td align="char">401</td><td></td></tr><tr><td align="left">Year of diagnosis, <italic>n</italic> (%)</td><td></td><td></td><td align="char">&lt;0.0001</td><td></td><td></td><td align="char">1</td></tr><tr><td align="left"> 1999–2003</td><td align="char">178 (36)</td><td align="char">1109 (28)</td><td></td><td align="char">151 (38)</td><td align="char">151 (38)</td><td></td></tr><tr><td align="left"> 2004–2006</td><td align="char">191 (39)</td><td align="char">1117 (28)</td><td></td><td align="char">157 (39)</td><td align="char">157 (39)</td><td></td></tr><tr><td align="left"> 2007–2010</td><td align="char">123 (25)</td><td align="char">1752 (44)</td><td></td><td align="char">93 (23)</td><td align="char">93 (23)</td><td></td></tr><tr><td align="left">Age band, <italic>n</italic> (%)</td><td></td><td></td><td align="char">&lt;0.0002</td><td></td><td></td><td align="char">0.86</td></tr><tr><td align="left"> 50–59 yr</td><td align="char">102 (21)</td><td align="char">567 (14)</td><td></td><td align="char">83 (21)</td><td align="char">81 (20)</td><td></td></tr><tr><td align="left"> 60–72 yr</td><td align="char">390 (79)</td><td align="char">3411 (86)</td><td></td><td align="char">318 (79)</td><td align="char">320 (80)</td><td></td></tr><tr><td align="left">Serum PSA, <italic>n</italic> (%)</td><td></td><td></td><td align="char">&lt;0.0001</td><td></td><td></td><td align="char">0.48</td></tr><tr><td align="left"> &lt;10 ng/ml</td><td align="char">160 (33)</td><td align="char">728 (18)</td><td></td><td align="char">149 (37)</td><td align="char">144 (36)</td><td></td></tr><tr><td align="left"> 10–20 ng/ml</td><td align="char">116 (24)</td><td align="char">752 (19)</td><td></td><td align="char">112 (28)</td><td align="char">117 (29)</td><td></td></tr><tr><td align="left"> 20–50 ng/ml</td><td align="char">141 (28)</td><td align="char">1086 (27)</td><td></td><td align="char">90 (22)</td><td align="char">75 (19)</td><td></td></tr><tr><td align="left"> 50–100 ng/ml</td><td align="char">49 (10)</td><td align="char">462 (12)</td><td></td><td align="char">24 (6)</td><td align="char">30 (7)</td><td></td></tr><tr><td align="left"> &gt;100 ng/ml</td><td align="char">26 (5)</td><td align="char">769 (19)</td><td></td><td align="char">26 (6)</td><td align="char">35 (9)</td><td></td></tr><tr><td align="left"> Unknown</td><td align="char">0(0)</td><td align="char">181 (5)</td><td></td><td align="char">0 (0)</td><td align="char">0 (0)</td><td></td></tr><tr><td align="left">Mean PSA, ng/ml (median)</td><td align="char">32.6 (16.7)</td><td align="char">201.1 (26.5)</td><td></td><td align="char">31.7 (14)</td><td align="char">217.2 (13)</td><td></td></tr><tr><td align="left">Gleason score, <italic>n</italic> (%)</td><td></td><td></td><td align="char">&lt;0.0001</td><td></td><td></td><td align="char">1</td></tr><tr><td align="left"> &lt;7</td><td align="char">112 (23)</td><td align="char">473 (12)</td><td></td><td align="char">93 (23)</td><td align="char">92 (23)</td><td></td></tr><tr><td align="left"> 7</td><td align="char">259 (53)</td><td align="char">1300 (33)</td><td></td><td align="char">222 (55)</td><td align="char">223 (55)</td><td></td></tr><tr><td align="left"> &gt;7</td><td align="char">115 (23)</td><td align="char">1654 (42)</td><td></td><td align="char">86 (21))</td><td align="char">86 (21)</td><td></td></tr><tr><td align="left"> Unknown</td><td align="char">6 (10</td><td align="char">551 (14)</td><td></td><td align="char">0 (0)</td><td align="char">0 (0)</td><td></td></tr><tr><td align="left">Mean Gleason score (median)</td><td align="char">7.1 (7)</td><td align="char">7.6 (7)</td><td></td><td align="char">7.1 (7)</td><td align="char">7.0 (7)</td><td></td></tr><tr><td align="left">Clinical stage, <italic>n</italic> (%)</td><td></td><td></td><td align="char">&lt;0.0001</td><td></td><td></td><td align="char">0.18</td></tr><tr><td align="left"> T1</td><td align="char">17 (4)</td><td align="char">989 (25)</td><td></td><td align="char">16 (4)</td><td align="char">29 (7)</td><td></td></tr><tr><td align="left"> T2</td><td align="char">42 (8)</td><td align="char">750 (19)</td><td></td><td align="char">42 (10)</td><td align="char">29 (7)</td><td></td></tr><tr><td align="left"> T3</td><td align="char">305 (62)</td><td align="char">1063 (27)</td><td></td><td align="char">301 (75)</td><td align="char">298 (74)</td><td></td></tr><tr><td align="left"> T4</td><td align="char">5 (10</td><td align="char">44 (1)</td><td></td><td align="char">4 (1)</td><td align="char">5 (1)</td><td></td></tr><tr><td align="left"> M1 or N1</td><td align="char">37 (8)</td><td align="char">1132 (28)</td><td></td><td align="char">37 (9)</td><td align="char">40 (10)</td><td></td></tr><tr><td align="left"> T stage unknown</td><td align="char">86 (18)</td><td align="char">0 (0)</td><td></td><td align="char">1 (1)</td><td align="char">0 (0)</td><td></td></tr><tr><td align="left">Follow-up (yr)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> Mean</td><td align="char">7.5</td><td align="char">5.5</td><td></td><td align="char">7.7</td><td align="char">7.5</td><td></td></tr><tr><td align="left"> Median</td><td align="char">7.4</td><td align="char">5</td><td></td><td align="char">7.6</td><td align="char">7.6</td><td></td></tr><tr><td align="left"> Interquartile range</td><td align="char">5.5–9.7</td><td align="char">3.1–7.8</td><td></td><td align="char">5.5–9.8</td><td align="char">5.1–9.8</td><td></td></tr></tbody></table><table-wrap-foot><fn><p>ACN = Anglia Cancer Network; PSA = prostate-specific antigen.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0005"><label>a</label><p id="npar0005"><italic>p</italic> value for χ<sup>2</sup> test for heterogeneity between unmatched and matched ProtecT advanced cases and ACN controls.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl0010" position="float"><label>Table 2</label><caption><p>Primary treatments and death rates among matched ProtecT cases and Anglia Cancer Network (ACN) controls</p></caption><alt-text id="at2">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Treatment</th><th colspan="3" align="center">Matched ProtecT cases<hr></hr></th><th colspan="3" align="center">Matched ACN controls<hr></hr></th></tr><tr><th></th><th align="center"><italic>N</italic></th><th colspan="2" align="center">Deaths, <italic>n</italic> (%)<hr></hr></th><th align="center"><italic>n</italic></th><th colspan="2" align="center">Deaths, <italic>n</italic> (%)<hr></hr></th></tr><tr><th></th><th></th><th align="center">PCS</th><th align="center">AC</th><th></th><th align="center">PCS</th><th align="center">AC</th></tr></thead><tbody><tr><td align="left">RP</td><td align="char">47</td><td align="char">1 (4)</td><td align="char">2 (4)</td><td align="char">150</td><td align="char">5 (3)</td><td align="char">12 (8)</td></tr><tr><td align="left">RT + ADT <xref rid="tblfn0010" ref-type="table-fn">a</xref></td><td align="char">200</td><td align="char">11 (6)</td><td align="char">31 (16)</td><td align="char">127</td><td align="char">6 (5)</td><td align="char">20 (16)</td></tr><tr><td align="left">Nonradical <xref rid="tblfn0015" ref-type="table-fn">b</xref></td><td align="char">105</td><td align="char">19 (18)</td><td align="char">37 (35)</td><td align="char">114</td><td align="char">51 (45)</td><td align="char">68 (60)</td></tr><tr><td align="left">Unknown</td><td align="char">49</td><td align="char">6 (12)</td><td align="char">19 (38)</td><td align="char">10</td><td align="char">1 (10)</td><td align="char">3 (3)</td></tr><tr><td align="left">Total</td><td align="char">401</td><td align="char">37 (9)</td><td align="char">89 (22)</td><td align="char">401</td><td align="char">63 (16)</td><td align="char">103 (26)</td></tr></tbody></table><table-wrap-foot><fn><p>RP = radical prostatectomy; ADT = androgen deprivation therapy; PCS = prostate cancer–specific; AC = all causes.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0010"><label>a</label><p id="npar0010">Adjuvant ADT was given in combination with radical radiotherapy in 93% of ProtecT cases and 88% of ACN controls.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn0015"><label>b</label><p id="npar0015">Nonradical treatment includes primary ADT, palliative chemotherapy, palliative radiotherapy, and monitoring.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tbl0015" position="float"><label>Table 3</label><caption><p>Cox proportional hazards survival analysis</p></caption><alt-text id="at3">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th align="left">Variable</th><th align="center">Reference</th><th colspan="4" align="center">Univariate analysis<hr></hr></th><th colspan="4" align="center">Multivariate analysis<hr></hr></th></tr><tr><th></th><th align="center">category</th><th colspan="2" align="center">Prostate cancer–specific survival<hr></hr></th><th colspan="2" align="center">Overall survival<hr></hr></th><th colspan="2" align="center">Prostate cancer–specific survival<hr></hr></th><th colspan="2" align="center">Overall survival<hr></hr></th></tr><tr><th></th><th></th><th align="center">HR (95% CI)</th><th align="center"><italic>p</italic> value</th><th align="center">HR (95% CI)</th><th align="center"><italic>p</italic> value</th><th align="center">HR (95% CI)</th><th align="center"><italic>p</italic> value</th><th align="center">HR (95% CI)</th><th align="center"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">ProtecT cases</td><td align="left">ACN controls</td><td align="char">0.29 (0.21–0.38)</td><td align="char">&lt;0.0001</td><td align="char">0.45 (0.38–0.55)</td><td align="char">&lt;0.0001</td><td align="char">0.47 (0.34–0.66)</td><td align="char">&lt;0.0001</td><td align="char">0.70 (0.56–0.88)</td><td align="char">&lt;0.002</td></tr><tr><td align="left">Year of diagnosis</td><td align="left">1999–2009</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> 2004–2006</td><td></td><td align="char">0.63 (0.55–0.72)</td><td align="char">&lt;0.0001</td><td align="char">0.71 (0.63–0.79)</td><td align="char">&lt;0.0001</td><td align="char">0.55 (0.46–0.65)</td><td align="char">&lt;0.0001</td><td align="char">0.69 (0.60–0.79)</td><td align="char">&lt;0.0001</td></tr><tr><td align="left"> 2007–2010</td><td></td><td align="char">0.48 (0.41–0.58)</td><td align="char">&lt;0.0001</td><td align="char">0.55 (0.48–0.64)</td><td align="char">&lt;0.0001</td><td align="char">0.48 (0.38–0.60)</td><td align="char">&lt;0.0001</td><td align="char">0.59 (0.50–0.71)</td><td align="char">&lt;0.0001</td></tr><tr><td align="left">Age band</td><td align="left">50–59 yr</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> 60–66 yr</td><td></td><td align="char">0.90 (0.75–1.07)</td><td align="char">0.24</td><td align="char">1.09 (0.93–1.28)</td><td align="char">0.29</td><td align="char">0.89 (0.71–1.10)</td><td align="char">0.28</td><td align="char">1.06 (0.88–1.29)</td><td align="char">0.52</td></tr><tr><td align="left"> 67–72 yr</td><td></td><td align="char">1.12 (0.94–1.33)</td><td align="char">0.20</td><td align="char">1.56 (1.34–1.81)</td><td align="char">&lt;0.0001</td><td align="char">0.97 (0.79–1.19)</td><td align="char">0.75</td><td align="char">1.43 (1.19–1.71)</td><td align="char">&lt;0.0001</td></tr><tr><td align="left">PSA</td><td align="left">0–10 ng/ml</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> 10–20 ng/ml</td><td></td><td align="char">1.23 (0.93–1.62)</td><td align="char">0.14</td><td align="char">1.37 (1.12–1.67)</td><td align="char">0.002</td><td align="char">1.05 (0.78–1.40)</td><td align="char">0.76</td><td align="char">1.22 (0.99–1.50)</td><td align="char">0.065</td></tr><tr><td align="left"> 20–50 ng/ml</td><td></td><td align="char">1.58 (1.23–2.01)</td><td align="char">&lt;0.0001</td><td align="char">1.57 (1.31–1.89)</td><td align="char">&lt;0.0001</td><td align="char">1.48 (1.14–1.93)</td><td align="char">&lt;0.003</td><td align="char">1.52 (1.25–1.85)</td><td align="char">&lt;0.0001</td></tr><tr><td align="left"> 50–100 ng/ml</td><td></td><td align="char">2.57 (1.97–3.36)</td><td align="char">&lt;0.0001</td><td align="char">2.20 (1.80–2.71)</td><td align="char">&lt;0.0001</td><td align="char">1.80 (1.35–2.43)</td><td align="char">&lt;0.0001</td><td align="char">1.66 (1.32–2.08)</td><td align="char">&lt;0.0001</td></tr><tr><td align="left"> &gt;100 ng/ml</td><td></td><td align="char">8.38 (6.70–10.5)</td><td align="char">&lt;0.0001</td><td align="char">5.87 (4.93–6.98)</td><td align="char">&lt;0.0001</td><td align="char">2.65 (2.02–3.45)</td><td align="char">&lt;0.0001</td><td align="char">2.43 (1.96–2.98)</td><td align="char">&lt;0.0001</td></tr><tr><td align="left">Combined Gleason</td><td align="left">&lt;7</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> 7</td><td></td><td align="char">1.39 (1.05–1.84)</td><td align="char">0.02</td><td align="char">1.04 (0.86–1.26)</td><td align="char">0.68</td><td align="char">1.66 (1.22–2.26)</td><td align="char">&lt;0.001</td><td align="char">1.18 (0.96–1.44)</td><td align="char">0.12</td></tr><tr><td align="left"> &gt;7</td><td></td><td align="char">4.13 (3.18–5.36)</td><td align="char">&lt;0.0001</td><td align="char">2.47 (2.08–2.93)</td><td align="char">&lt;0.0001</td><td align="char">4.01 (3.0–5.37)</td><td align="char">&lt;0.0001</td><td align="char">2.45 (2.01–2.96)</td><td align="char">&lt;0.0001</td></tr><tr><td align="left">Clinical stage</td><td align="left">T1/T2</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> T3</td><td></td><td align="char">0.71 (0.57–0.88)</td><td align="char">&lt;0.002</td><td align="char">0.70 (0.60–0.81)</td><td align="char">&lt;0.0001</td><td align="char">1.21 (0.96–1.53)</td><td align="char">0.11</td><td align="char">1.08 (0.92–1.29)</td><td align="char">0.32</td></tr><tr><td align="left"> T4</td><td></td><td align="char">2.10 (1.18–3.76)</td><td align="char">0.01</td><td align="char">1.51 (0.95–2.43)</td><td align="char">0.08</td><td align="char">2.74 (1.52–4.92)</td><td align="char">&lt;0.001</td><td align="char">1.96 (1.22–3.15)</td><td align="char">&lt;0.005</td></tr><tr><td align="left"> M1 or N1</td><td></td><td align="char">8.22 (7.08–9.55)</td><td align="char">&lt;0.0001</td><td align="char">4.88 (4.36–5.47)</td><td align="char">&lt;0.0001</td><td align="char">5.79 (4.82–6.95)</td><td align="char">&lt;0.0001</td><td align="char">3.53 (3.07–4.10)</td><td align="char">&lt;0.0001</td></tr></tbody></table><table-wrap-foot><fn><p>HR = hazard ratio; CI = confidence interval; ACN = Anglia Cancer Network; PSA = prostate-specific antigen.</p></fn></table-wrap-foot></table-wrap></floats-group></article>